This letter highlights diagnostic challenges in attributing clinical improvement to IVIg in mucocutaneous eruptions, indicating the need for precise classification.
This letter questions whether some IVIg-treated cases classified as erythema multiforme major may instead represent reactive infectious mucocutaneous eruption. Diagnostic heterogeneity, concomitant therapies and inconsistencies in the reported data limit attribution of clinical improvement specifically to IVIg, underscoring the need for explicit phenotypic classification before therapeutic inference.
No takes yet. Share an insight, caveat, or question.
Fatih Kaplan (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: